🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Singapore / NCT07697612
Starting soon Not applicable

Durian Consumption in Adults With Type 2 Diabetes Mellitus

NCT07697612 · tracked via the Priya Life Science Singapore tracker
Phase
Not applicable
Started
2026-08
Last updated
2026-07-13

Condition(s) studied

Type 2 Diabetes

Investigational drug(s) / intervention(s)

Durian pulp

Durian pulp: Fresh durian pulp supplied by the study team. Participants consume 100 g on Day 1, then 200 g daily from Day 2 onward during the durian phase for 10 to 14 days. Participants record the timing and amount consumed each day.

Study summary

This single-arm clinical trial investigates the effects of daily durian consumption on the gut microbiome, host metabolome, and glucose metrics in adults with type 2 diabetes mellitus (T2DM). Forty adults with T2DM will undergo a pre-durian phase, a durian consumption phase, and a post-durian phase, each lasting 10 to 14 days. Participants will attend five visits at Singapore General Hospital for clinical assessments, continuous glucose monitoring, fasting blood collection, stool sample collection, and dietary and stool record submission. The study aims to determine whether durian consumption alters microbiome and metabolomic profiles and whether it affects glycemic measures in adults with T2DM.

Eligibility

Sex
ALL
Min age
21 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 21 to 70 years. 2. Diagnosis of type 2 diabetes mellitus. 3. Agrees to consume durian for 2 weeks. 4. Body mass index 25 to 40 kg/m². Exclusion Criteria: 1. Known or suspected intolerance or allergy to durian. 2. Known skin reaction to adhesives used in a continuous glucose sensor. 3. Uncontrolled diabetes (HbA1c greater than 8.5%). 4. Severe hypertriglyceridemia (triglycerides greater than 4.5 mmol/L). 5. Smoking. 6. Previous gastrointestinal surgeries, including cholecystectomy, gastrectomy, bariatric surgery, or colectomy. 7. Inflammatory bowel disease. 8. Glomerular filtration rate less than 30 mL/min. 9. ALT greater than 3 times upper limit of normal. 10. AST greater than 3 times upper limit of normal. 11. Liver cirrhosis. 12. Significant alcohol consumption, defined as more than 20 g/day for women and more than 30 g/day for men. 13. Pregnant, breastfeeding, or intending to conceive during the study. 14. Current hemorrhoids or piles causing rectal bleeding during stool passage. 15. Systemic steroid use. 16. Insulin use. 17. Weight loss medications, including GLP-1 receptor agonists, orlistat, or phentermine. 18. Antibiotic, prebiotic, probiotic, vitamin C, or traditional Chinese medicine use in the last 1 month. 19. Uncontrolled thyroid disease. 20. Any factor likely to limit adherence to study protocol, including dementia, substance abuse, poor appointment adherence, or family concerns regarding participation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Singapore General Hospital Singapore Singapore

More Singapore General Hospital trials in Singapore

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07697612 on ClinicalTrials.gov ↗ ← All trials in Singapore